Eli Lilly is accelerating acquisitions in cancer and sleep disorder treatments as it looks beyond obesity drugs. As of August, acquisitions announced in 2026 totaled approximately $28 billion (approximately ¥4.4 trillion), the highest level in the past 10 years.
Eli Lilly has been actively pursuing acquisitions since the beginning of 2026. As of August, the total value of announced acquisitions had reached approximately $28 billion, the largest scale in the past 10 years. Building on the success of its obesity drugs, the company appears to be pursuing a policy of expanding its growth opportunities through the acquisition of external assets.
Reported potential areas for future investment include cancer and sleep disorder treatments, with the company aiming to establish growth drivers to follow its diabetes and obesity drugs.
Eli Lilly Chairman David Ricks (デービッド・リックス) was reported to have said, “We have been highly successful in the obesity field and have the capacity to invest in the future. There is excellent innovation outside the company that is worthy of partnering with.”
Eli Lilly is expanding its portfolio beyond blood glucose control through acquisitions and partnerships in areas including cancer and neuroscience.